ACADEMIC AND INDUSTRY PERSPECTIVES ON PHARMACOGENOMICS: DRUG OPTIMIZATION

被引：0
|
作者：
Shuldiner, Alan
机构：
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2019年 / 34卷 / 01期
关键词：
D O I：
10.1016/j.dmpk.2018.09.030
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
S8
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [41] Pharmacogenomics and drug resistant epilepsy
    不详
    ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (11) : 1000 - 1000
  • [42] Improving drug response with pharmacogenomics
    Nicholls, H
    DRUG DISCOVERY TODAY, 2003, 8 (07) : 281 - 282
  • [43] Evolving Research and Stakeholder Perspectives on Pharmacogenomics
    Beitelshees, Amber L.
    Veenstra, David L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (11): : 1252 - 1253
  • [44] Implications of Pharmacogenomics for Drug Development
    Kirk, Randal J.
    Hung, Jeffrey L.
    Horner, Scorr R.
    Perez, Jeffrey T.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (12) : 1484 - 1497
  • [45] PHARMACOGENOMICS OF ANTICOAGULANT AND ANTIPLATELET DRUG
    Shin, Jae-Gook
    DRUG METABOLISM REVIEWS, 2008, 40 : 15 - 16
  • [46] Role of pharmacogenomics in drug development
    Hakonarsson, H
    Stefansson, K
    DRUG DEVELOPMENT RESEARCH, 2004, 62 (02) : 86 - 96
  • [47] Pharmacogenomics In Pharmacy Practice: Current Perspectives
    Elewa, Hazem
    Awaisu, Ahmed
    INTEGRATED PHARMACY RESEARCH AND PRACTICE, 2019, 8 : 97 - 104
  • [48] Pharmacogenomics and adverse drug reactions
    Chiba, K
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 46P - 46P
  • [49] Pharmacogenomics of psychiatric drug treatment
    Mancama, D
    Arranz, MJ
    Kerwin, RW
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2003, 5 (06) : 642 - 649
  • [50] Pharmacogenomics of adverse drug reactions
    Ann K Daly
    Genome Medicine, 5
12345